Kane Biotech Enters into Material Transfer and Evaluation Agreement with Ward Industries Group

WINNIPEG, MANITOBA, Jul 22 (MARKET WIRE) --
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in
the development of products that prevent and remove microbial biofilms,
is pleased to announce that the Company has entered into a material
transfer and evaluation agreement with Ward Industries Group of Monaghan,
Ireland, a specialist provider and innovator of unique ingredients to the
international human and pet food industries.

In this agreement, Ward Industries Group will be evaluating Kane
Biotech's antibiofilm and antimicrobial technologies for the development
of a novel Companion Animal Product. Upon completion of this agreement,
Ward Industries will have an exclusive option to license the technology
from Kane Biotech for the development of this product for the
international Companion Animal Markets. The type of product and specific
field of use are not disclosed.

"The humanization of pet care is growing rapidly around the world and we
have embarked on a journey of innovation into this market for the
development of unique products," stated Paul Ward, Managing Director of
Ward Industries. "Ward has spent considerable time and resources
searching the world for antibiofilm and antimicrobial ingredients that
offer promise in the development of our unique companion animal offerings
and we are very pleased to have the opportunity to evaluate Kane
Biotech's technology and intellectual property for this international
market opportunity".

"Ward has assembled a high caliber international specialist research and
development team and we look forward to working with them as they test
our technologies for the companion animal market," stated Gord Froehlich,
President and CEO of Kane Biotech.

About Ward Industries Group

Ward Industries Group is a specialist provider of high quality, organic
and non-organic niche ingredients, servicing and fulfilling the food and
pet food manufacturing industry's needs. The company also provides a
complete range of organic and non-organic ingredients to International
pet food manufacturers and has established long term relationships with
its food and pet food manufacturing customers. Over the last number of
years Ward has embarked on a journey of innovation into companion animal
markets and is currently developing a number of unique health solutions
for international companion animal markets.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of
products to prevent and remove biofilms. Biofilms are a major cause of a
number of serious medical problems including tooth decay, chronic
infections and medical device related infections. They develop on
surfaces such as teeth, catheters, prosthetic implants, lungs and the
urogenital tract. Biofilms are pervasive, costly to deal with and are
involved in approximately 80% of all human bacterial infections.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable Canadian
provincial securities legislation (collectively, "forward-looking
statements"). These forward-looking statements relate to, among other
things, our objectives, goals, targets, strategies, intentions, plans,
beliefs, estimates and outlook, including, without limitation, our
anticipated future operating results, and can, in some cases, be
identified by the use of words such as "believe," "anticipate," "expect,"
"intend," "plan," "will," "may" and other similar expressions. In
addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking
statements.

These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors
or assumptions are applied in making forward-looking statements, and
actual results may differ materially from those expressed or implied in
such statements. Important factors that could cause actual results to
differ materially from these expectations include, among other things:
Kane's early stage of development, lack of product revenues and history
of operating losses, uncertainties related to clinical trials and product
development, rapid technological change, uncertainties related to
forecasts, competition, potential product liability, additional financing
requirements and access to capital, unproven markets, supply of raw
materials, income tax matters, management of growth, partnerships for
development and commercialization of technology, effects of insurers'
willingness to pay for products, system failures, dependence on key
personnel, foreign currency risk, risks related to regulatory matters and
risks related to intellectual property and other risks detailed from time
to time in Kane's filings with Canadian securities regulatory
authorities, as well as Kane's ability to anticipate and manage the risks
associated with the foregoing. Kane cautions that the foregoing list of
important factors that may affect future results is not exhaustive. When
relying on Kane's forward-looking statements to make decisions with
respect to Kane, investors and others should carefully consider the
foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and
prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management believes
to be reasonable assumptions, Kane cannot provide assurance that actual
results will be consistent with these forward-looking statements. Kane
undertakes no obligation to update or revise any forward-looking
statement.

The TSX Venture Exchange does not accept responsibility
for the adequacy or accuracy of this release.

Contacts:
Kane Biotech Inc.
Justin Gagnon
Manager, Investor Relations
(204) 478-5602
(204) 453-1314 (FAX)
Email: jgagnon@kanebiotech.com
Website: www.kanebiotech.com

Copyright 2008, Market Wire, All rights reserved.

-0-